Jin Yang Pharmaceutical Lowers CB Conversion Price (5,138→4,668 Won), Increasing Potential Dilution Risk
Jin Yang Pharmaceutical adjusted the conversion price of its 1st series convertible bonds (CB) from 5,138 won to 4,668 won, effective May 26, 2026, due to market price decline.
The lower conversion price increases the potential number of shares issuable from the outstanding 400 million won CB from 77,851 to 85,689 shares, a ~10.1% increase, diluting existing shareholders.
The company has repeatedly adjusted conversion prices, exercised conversion rights, and sold its own CBs, leading to continuous share count growth, posing long-term dilution risk and capping stock upside.
[AI Comprehensive Analysis]The conversion price adjustment is a mechanical response to market price decline, limiting short-term impact. However, the company's frequent CB-related disclosures maintain persistent dilution concerns, warranting cautious investment consideration.